Short-term ADT with RT for localized prostate cancer

The RTOG 94-08 clinical trial was designed to test the idea that just 4 months of hormone therapy, administered  before and during radiation therapy, would improved the overall survival of patients diagnosed with clinical stage T1b-T2b prostate cancer and a PSA level equal to or lower than 20 ng/ml. … READ MORE …

Phase III data on early chemohormonal therapy in high-risk patients

Results of a study (the GETUG 12 trial) presented today at the ASCO 2010 Genitourinary Cancer Symposium in San Francisco suggest that the addition of docetaxel-based chemotherapy to androgen deprivation and radiation therapy may impact biochemical recurrence of prostate cancer in high risk patients with localized disease — but it will take a while before truly convincing results are available. … READ MORE …

Where do newly diagnosed patients seek information?

A recent report in Urology focused on the role of information sources in the treatment decision-making process of men diagnosed with localized prostate cancer. … READ MORE …

Use of aids to erectile function after treatment for localized disease

A new study provides us with evaluated associations between demographic and clinical characteristics, quality of life outcome measures, and the use of aids to erectile function in men with prostate cancer. … READ MORE …